M. Irizarry

Lecanemab in Early Alzheimer's Disease.

R. Bateman, B. Vellas, C. V. van Dyck, 2022, The New England journal of medicine.

Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System

D. Berlowitz, Quanwu Zhang, A. A. Tahami Monfared, 2022, Neurology and Therapy.

Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials

Nancy B. Lynn, S. Kremen, P. Aisen, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study

S. de Santi, N. Roé-Vellvé, Audrey Perrotin, 2022, Alzheimer's Research & Therapy.

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease

Keith A. Johnson, R. Sperling, P. Aisen, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

R. Bateman, E. McDade, J. Cummings, 2022, Alzheimer's research & therapy.

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

R. Sperling, R. Raman, K. Ernstrom, 2023, Annals of neurology.